Dendritic cell vaccination and immune monitoring.
- Aarntzen, E.H.J.G.
- Figdor, C.G.
- Adema, G.J.
- Punt, C.J.A.
- Vries, I.J.M. de
Publication date
January 2008
DOIAbstract
We exploited dendritic cells (DC) to vaccinate melanoma patients. We recently demonstrated a statistical significant correlation between favorable clinical outcome and the presence of vaccine-related tumor antigen-specific T cells in delayed type hypersensitivity (DTH) skin biopsies. However, favorable clinical outcome is only observed in a minority of the treated patients. Therefore, it is obvious that current DC-based protocols need to be improved. For this reason, we study in small proof of principle trials the fate, interactions and effectiveness of the injected DC
Add to ORKG